TARS
NASDAQTarsus Pharmaceuticals Inc.
Price$59.80+0.44 (+0.74%)
01:30 PM07:45 PM
News · 26 weeks850%
2026-01-182026-07-12
Mix3990d
- Insider18(46%)
- SEC Filings9(23%)
- Other7(18%)
- Earnings3(8%)
- Analyst1(3%)
- Offering1(3%)
Latest news
25 items- SECTarsus Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update8-K - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)
- PRTarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of GrowthIRVINE, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) today announced that Aziz Mottiwala, Chief Commercial Officer, is departing the Company to pursue a new opportunity as Chief Executive Officer of a public medical device company. Effective immediately, Neera Clase, formerly Senior Vice President of Market Access, will serve as Interim Chief Commercial Officer while Tarsus conducts a search for a permanent successor. Since joining Tarsus in 2021, Ms. Clase has played an integral role in the Company's evolution from a clinical-stage organization to a successful commercial biopharmaceutical company with one of the best launches in eye care to date. H
- SECTarsus Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities8-K - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)
- PRTarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101IRX-101 targets a significant need for millions of patients facing vision loss and has the potential to improve the standard of care Positive Phase 2b/3 data and an FDA-aligned Phase 3 program provide a clear and near-term path forward; transaction structured to align economics with future value creation Tarsus to host investor conference call today, July 8, 2026, at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) today announced the acquisition of iRenix Medical, Inc., a privately held, clinical-stage ophthalmic biopharmaceutical company and developer of IRX-101, an investigational ocular antiseptic with the poten
- INSIDERSEC Form 4 filed by Director Chaudhuri Bhaskar4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERSEC Form 4 filed by Director Morrison Scott W4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERSEC Form 4 filed by Director Goldberg Andrew D.4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERSEC Form 4 filed by Director Goodrich Katherine4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERSEC Form 4 filed by Director Yarno Wendy L4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERSEC Form 4 filed by Director Pyott David E I4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERSEC Form 4 filed by Director Link William J Phd4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- SECTarsus Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)
- INSIDERPresident/CEO and Board Chair Azamian Bobak R. sold $615,488 worth of shares (10,000 units at $61.55) as part of a pre-agreed trading plan (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDEROfficer Farrow Jeffrey S converted options into 27,881 shares and sold $877,436 worth of shares (14,396 units at $60.95), increasing direct ownership by 31% to 56,801 units (SEC Form 4) (withholding tax)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERDirector Goodrich Katherine sold $183,384 worth of shares (2,954 units at $62.08) as part of a pre-agreed trading plan, decreasing direct ownership by 57% to 2,233 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERDirector Link William J Phd sold $776,495 worth of shares (12,500 units at $62.12) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 106,786 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- SECSEC Form 144 filed by Tarsus Pharmaceuticals Inc.144 - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
- INSIDERDirector Morrison Scott W converted options into 2,954 shares, increasing direct ownership by 63% to 7,638 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERDirector Chaudhuri Bhaskar converted options into 2,954 shares, increasing direct ownership by 34% to 11,654 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERDirector Yarno Wendy L converted options into 2,954 shares, increasing direct ownership by 22% to 16,654 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERDirector Goodrich Katherine converted options into 2,954 shares, increasing direct ownership by 132% to 5,187 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERDirector Link William J Phd converted options into 2,954 shares, increasing direct ownership by 3% to 119,286 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- INSIDERDirector Goldberg Andrew D. converted options into 2,954 shares, increasing direct ownership by 18% to 19,654 units (SEC Form 4)4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
- SECSEC Form 144 filed by Tarsus Pharmaceuticals Inc.144 - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
- PRAchieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of DirectorsSEATTLE and VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. ("Achieve" or the "Company") (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that Jeffrey Farrow and Reid Waldman, MD have been appointed to its Board of Directors. "Jeffrey and Reid are exactly the kinds of operators you want around a board table when a company is preparing for its first launch," said Lucian Iancovici, MD, incoming Chairman of the Board of Directors of Achieve. "Jeffrey has lived the playbook of taking specialty companies from lat
TARS FAQ
7 questionsWhat does Tarsus Pharmaceuticals Inc. do?
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in...Where does TARS stock trade?
Tarsus Pharmaceuticals Inc. (TARS) is listed on NASDAQ.What sector and industry is TARS in?
Tarsus Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Tarsus Pharmaceuticals Inc. go public?
Tarsus Pharmaceuticals Inc. (TARS) completed its IPO in 2020.What are analysts saying about TARS?
Tarsus Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Oppenheimer: Outperform on 2026-04-24. Recent price targets range from $1900.00 to $4400.00.What companies are similar to TARS?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare TARS side-by-side with any of them on Quantisnow.How can I track TARS on Quantisnow?
Quantisnow aggregates Tarsus Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TARS to receive live email and push alerts on every new disclosure.